|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
Within the scope of increasing the paid-in capital of Gen Pharma Caucasus Manufacturing Operations MMC ("Gen Caucasus"), which is 66.00% owned by Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("GEN") and is also constructing Azerbaijan's first pharmaceutical production facility, from 15.300.000,00 Azerbaijan Manat (AZN) to AZN 35.700.000,00 (USD 21.000.000,00): GEN, which participated in the capital increase process of Gen Caucasus with its shareholding ratio of 66.00% remaining fixed, has completed its capital payment amounting to USD 7.920.000,00 (AZN 13.464.000,00). Upon the completion of the capital payments by Gen Kafkasya's other partners, Gen Kafkasya's current capital will be AZN 35,700,000.00, and GEN's share in the capital will be AZN 23,562,000. The shareholding ratios of 'Azerbaijan Business Development Fund' (Azərbaycan Biznesinin İnkişafı Fondu / ABİF) at 29.00% and SIA Pharmaceutical at 5.00% will also remain fixed.
|
||||||||